Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Kristina Iribarren; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Špíšek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2015.1088631

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Kristina Iribarren, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

109 Citaten (Scopus)

Samenvatting

ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

Originele taal-2	Engels
Tijdschrift	OncoImmunology
Volume	5
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1080/2162402X.2015.1088631
Status	Gepubliceerd - 3 mrt. 2016
Extern gepubliceerd	Ja

Toegang tot document

10.1080/2162402X.2015.1088631

Citeer dit

@article{eb6cc60a1eaa4b1caf9b96cf08c92a8e,

title = "Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy",

abstract = "ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.",

keywords = "Ampligen{\texttrademark}, bacillus Calmette-Gu{\'e}rin, G100, Hiltonol{\texttrademark}, imiquimod, motolimod",

author = "Kristina Iribarren and Norma Bloy and Aitziber Buqu{\'e} and Isabelle Cremer and Alexander Eggermont and Fridman, {Wolf Herv{\'e}} and Jitka Fucikova and J{\'e}r{\^o}me Galon and Radek {\v S}p{\'i}{\v s}ek and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2016, {\textcopyright} Taylor & Francis Group, LLC.",

year = "2016",

month = mar,

day = "3",

doi = "10.1080/2162402X.2015.1088631",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "3",

}

TY - JOUR

T1 - Trial Watch

T2 - Immunostimulation with Toll-like receptor agonists in cancer therapy

AU - Iribarren, Kristina

AU - Bloy, Norma

AU - Buqué, Aitziber

AU - Cremer, Isabelle

AU - Eggermont, Alexander

AU - Fridman, Wolf Hervé

AU - Fucikova, Jitka

AU - Galon, Jérôme

AU - Špíšek, Radek

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2016/3/3

Y1 - 2016/3/3

N2 - ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

AB - ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

KW - Ampligen™

KW - bacillus Calmette-Guérin

KW - G100

KW - Hiltonol™

KW - imiquimod

KW - motolimod

UR - http://www.scopus.com/inward/record.url?scp=84961671432&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1088631

DO - 10.1080/2162402X.2015.1088631

M3 - Review article

AN - SCOPUS:84961671432

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 3

ER -

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit